www.fdanews.com/articles/205105-fluxoaxamine-slashes-covid-19-hospitalizations-study-finds
Fluxoaxamine Slashes COVID-19 Hospitalizations, Study Finds
November 1, 2021
A 10-day course of the inexpensive antidepressant fluvoaxamine cut the risk of COVID-19-related hospitalization by 32 percent in infected patients with comorbidities, a research team in Brazil has found.
And patients who took the drug as prescribed were 66 percent less likely to be hospitalized for the infection than patients who took a placebo, reported Gilmar Reis of the Pontifical Catholic University of Minas Gerais and colleagues in the journal Lancet Global Health.
The drug also more than halved mortality, from 2 percent in the placebo group to less than 1 percent in the treatment group.